You are here: Industry Insights > ProBioGen

News List

Immunogenesis, ProBioGen Enter Large-Scale Mfg. Pact contractpharma
March 26, 2020
To provide cell line development, process development and GMP manufacture of Immunogenesis’ lead immuno-oncology candidate.
ProBioGen, ImmunOs Ink Manufacturing Services Agreement contractpharma
March 03, 2020
ProBioGen will support ImmunOs in the development of their biologics using its DirectedLuck Transposase technology.
ImmunOs Therapeutics Selects ProBioGen for Development and Large-Scale Manufacturing Services prnasia
March 02, 2020
ProBioGen AG today announced that ImmunOs Therapeutics AG has signed a Manufacturing Services Agreement for their novel platform of multitasking biologics.
ProBioGen Inks Next Commercial GlymaxX® License with Roche b3cnewswire
January 16, 2020
ProBioGen AG has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.
ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule b3cnewswire
January 16, 2020
ProBioGen AG and Lava Therapeutics B.V. announced the closing of a cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.
DirectedLuck, a Transposase for Efficient Gene Delivery and High-Titer Cell Line Development b3cnewswire
November 13, 2019
ProBioGen AG, a premier German service & technology provider for complex biologics, announced the launch of DirectedLuck, a highly active transposase equipped for specific epigenetic targeting.
ProBioGen Licenses GlymaxX® Technology to Bayer b3cnewswire
September 17, 2019
ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, announced the closing of a license agreement with Bayer AG for the GlymaxX® Technology.
ProBioGen, Abcuro Ink GlymaxX Pact contractpharma
May 29, 2019
ProBioGen to provide cell line development leveraging its CHO.RiGHT expression platform through to GMP production.
ProBioGen and Abcuro Signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement b3cnewswire
May 24, 2019
ProBioGen and Abcuro Signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement
ProBioGen, Vaccitech Ink Cell Line License Agreement contractpharma
May 16, 2019
Will leverage ProBioGen’s AGE1.CR duck cell technology for large-scale manufacturing.

Previous page 1 2 3 4 5 6 Next page